BeBetter Med Inc
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-33
RECRUITING6
READOUTS ≤12 MONTHS1
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| BEBT-209 capsules NCT06998108 |
P3 | Recruiting | HR+/HER2- Locally Advanced, Metastatic Breast Cancer | 330 | 2025-12-31 |
| BEBT-109 Capsule NCT06706713 |
P2 | Recruiting | Non-Small Cell Lung Cancer; EGFR Exon 20 Insertion Mutation | 200 | 2025-12-31 |
| BEBT-109 Capsules NCT06514027 |
P2 | Recruiting | Non Small Cell Lung Cancer | 30 | 2027-06 |
| Ifupinostat Hydrochloride for Injection NCT07676175 |
P2 | Not yet recruiting | Previously Untreated Peripheral T-Cell Lymphoma | 120 | 2028-01-31 |
| BEBT-701 Injection NCT07368608 |
P1/2 | Recruiting | Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol | 340 | 2028-11-30 |
| Ifupinostat Hydrochloride for Injection NCT06792253 |
P3 | Recruiting | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 416 | 2028-12-31 |
| BEBT-209 capsules NCT07544056 |
P2/3 | Recruiting | Locally Advanced Triple-negative Breast Cancer; Metastatic Triple-negative Breast Cancer | 446 | 2030-06 |